• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Organogenesis Holdings Inc.

    8/7/25 4:27:20 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email
    S-8 1 d99134ds8.htm S-8 S-8

    AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 7, 2025

    REGISTRATION NO. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ORGANOGENESIS HOLDINGS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   98-1329150

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    85 Dan Road

    Canton, MA 02021

    (Address of principal executive offices, including zip code)

    Organogenesis Holdings Inc. 2018 Equity Incentive Plan

    (Full title of the plan)

     

     

    Lori Freedman

    Chief Administrative and Legal Officer

    Organogenesis Holdings Inc.

    85 Dan Road

    Canton, MA 02021

    (Name and address of agent for service)

    (781) 575-0775

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William R. Kolb

    Ryan M. Rourke Reed

    Foley Hoag LLP

    155 Seaport Boulevard

    Boston, Massachusetts 02210

    Telephone: (617) 832-1000

    Telecopy: (617) 832-7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☑
    Non-accelerated filer   ☐    Smaller Reporting Company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Organogenesis Holdings Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) to register an additional 15,900,000 shares of its Class A common stock, par value $0.0001 per share, that may be issued and sold under the Organogenesis Holdings Inc. 2018 Equity Incentive Plan, as amended (the “Plan”), following the amendment to the Plan that was approved by the Registrant’s stockholders at its annual meeting on June 20, 2024. This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities, and pursuant to that instruction, the contents of the Registration Statements on Form S-8 (File No. 333-229601 and File No.  333-268736) filed with the Securities and Exchange Commission on February  11, 2019 and December 9, 2022, respectively, are incorporated herein by reference.

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit
    Number

      

    Description

      4.1    Certificate of Incorporation of ORGO (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)
      4.2    Certificate of Amendment of Certificate of Incorporation of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 27, 2022)
      4.3    Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on November 12, 2024)
      4.4    Bylaws of ORGO (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)
      4.4+    2018 Equity Incentive Plan (as amended) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 21, 2024)
      5.1*    Opinion of Foley Hoag LLP
     23.1*    Consent of RSM US LLP
     23.2*    Consent of Foley Hoag LLP (included in the opinion filed as Exhibit 5.1)
     24.1*    Power of Attorney (included on the signature page hereto)
    107*    Filing Fee Table

     

    *

    Filed herewith.

    +

    Indicates management contract or compensatory plan.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Canton, Commonwealth of Massachusetts, on August 7, 2025.

     

    ORGANOGENESIS HOLDINGS INC.
    By:   /s/ Gary S. Gillheeney, Sr.
     

    Gary S. Gillheeney, Sr.

    President and Chief Executive Officer

    POWER OF ATTORNEY

    We, the undersigned officers and directors of Organogenesis Holdings Inc., hereby severally constitute and appoint each of Gary S. Gillheeney, Sr. and David Francisco, our true and lawful attorneys-in-fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Gary S. Gillheeney, Sr.

    Gary S. Gillheeney, Sr.

       Chief Executive Officer, President and Director
    (Principal Executive Officer)
      August 7, 2025

    /s/ David Francisco

    David Francisco

       Chief Financial Officer
    (Principal Financial and
    Accounting Officer)
      August 7, 2025

    /s/ Robert Ades

    Robert Ades

       Director   August 7, 2025

    /s/ Michael J. Driscoll

    Michael J. Driscoll

       Director   August 7, 2025

    /s/ Prathyusha Duraibabu

    Prathyusha Duraibabu

       Director   August 7, 2025

    /s/ Jon Giacomin

    Jon Giacomin

       Director   August 7, 2025

    /s/ Michele Korfin

    Michele Korfin

       Director   August 7, 2025

    /s/ Arthur S. Leibowitz

    Arthur S. Leibowitz

       Director   August 7, 2025


    /s/ Garrett Lustig

    Garrett Lustig

       Director   August 7, 2025

    /s/ Glenn H. Nussdorf

    Glenn H. Nussdorf

       Director   August 7, 2025

    /s/ Gilberto Quintero

    Gilberto Quintero

       Director   August 7, 2025
    Get the next $ORGO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Grow Brian exercised 4,060 shares at a strike of $2.47 and covered exercise/tax liability with 2,173 shares, increasing direct ownership by 0.28% to 672,377 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    8/13/25 4:08:38 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.19% to 189,165 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    7/18/25 4:13:38 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Organogenesis Holdings Inc.

    SCHEDULE 13G - Organogenesis Holdings Inc. (0001661181) (Subject)

    8/14/25 4:33:14 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Organogenesis Holdings Inc.

    S-8 - Organogenesis Holdings Inc. (0001661181) (Filer)

    8/7/25 4:27:20 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Organogenesis Holdings Inc.

    10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)

    8/7/25 4:16:48 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Organogenesis with a new price target

    Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

    6/28/24 8:20:16 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

    Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

    2/7/24 6:56:39 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Organogenesis with a new price target

    Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00

    6/15/23 7:30:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

    CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the

    7/22/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

    CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services' (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule and urges CMS to establish 2026 payment rates based on clinical value and relative cost. "We are pleased CMS is proposing a per centimeter square payment methodology based on FDA classification for skin substitutes i

    7/15/25 9:00:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

    CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the

    7/22/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

    CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

    5/8/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Leadership Updates

    Live Leadership Updates

    View All

    Organogenesis Expands Manufacturing Capacity to Support Future Growth

    CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

    11/22/24 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

    CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

    11/12/24 4:01:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    7/3/23 6:00:00 AM ET
    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

    SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 3:35:42 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care